Skip to main content

Advertisement

SpringerLink
Log in

Increase of vertebral density by combination therapy with pulsatile 1-38hPTH and sequential addition of calcitonin nasal spray in osteoporotic patients

  • Clinical Investigations
  • Published:
Calcified Tissue International Aims and scope Submit manuscript

Summary

Combination therapy with the biologically active (1–38) human parathyroid hormone peptide and calcitonin using pulsatile and sequential activation of the skeleton for 14 months in patients with low-turnover osteoporosis resulted in an increase in trabecular bone mass. These favorable responses were observed without any significant changes in cortical (forearm) bone mass content.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Podbesek RD, Stevenson R, Zanelli GD, Edouard C, Meunier PJ, Reeve J, Parsons JA (1981) Treatment with human parathyroid hormone fragment (hPTH 1–34) stimulates bone formation and intestinal calcium absorption in the greyhound: comparison with data from the osteoporosis trial. Int Congress Series Exc Medica 511:118–123

    Google Scholar 

  2. Reeve J, Hesp R, Williams D, Hulme P, Klenerman L, Zanelli JM, Darby AJ, Tregear GW, Parsons JA (1976) Anabolic effect of low doses of a fragment of human parathyroid hormone on the skeleton in postmenopausal osteoporosis. Lancet i:1035–1038

    Article  Google Scholar 

  3. Reeve J, Meunier PJ, Parsons JA, Bernat M, Bijvoet OLM, Courpron P, Edouard C, Klenerman L, Neer NM, Renier JC, Slovik D, Vismans FJFE, Potts JT Jr (1980) Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. B Med J 2:1340–1341

    Google Scholar 

  4. Frost HM (1979) Treatment of osteoporosis by manipulation of coherent bone cell populations. Clin Orth Rel Res 143:227–244

    Google Scholar 

  5. Parsons JA, Reit B (1974) Chronic response of dogs to parathyroid hormone infusion. Nature 250:254

    Article  PubMed  CAS  Google Scholar 

  6. Rasmussen H, Bordier P (1974) The physiological and cellular basis of metabolic bone disease. William and Wilkins, Baltimore, pp 305–314

    Google Scholar 

  7. Parsons JA, Meunier PJ, Podbesek RD, Reeve J, Stevenson RW (1981) Pathological and therapeutic implications of the cellular and humoral responses to parathyrin. Biochem Soc Trans 9:383–386

    PubMed  CAS  Google Scholar 

  8. Hesch RD, Heck J, Auf'mkolk B, Schettler TH, Atkinson MJ (1984) First clinical observations with hPTH (1–38), a more potent human parathyroid hormone peptide. Horm Metab Res 10:559–560

    Google Scholar 

  9. Atkinson MJ, Schettler TH, Bodenstein H, Hesch RD (1984) Osteoporosis: a bone turnover defect resulting from an elevated parathyroid bone concentration within the bone-marrow cavity? Klin Wochenschr 62:129–132

    Article  PubMed  CAS  Google Scholar 

  10. Parfitt AM (1976) The actions of parathyroid hormone on bone: relation to bone remodeling and turnover, calcium homeostasis, and metabolic bone disease. Metabolism 25:909–955

    Article  PubMed  CAS  Google Scholar 

  11. Parfitt AM (1976) PTH and bone cells: bone turnover and plasma calcium regulation, II. Metabolism 25:909–955

    Article  PubMed  CAS  Google Scholar 

  12. Parfitt AM (1976) PTH and osteoblasts: the relationship between bone turnover and bone loss and the state of the bones in primary hyperparathyroidism, III. Metabolism 25:1033–1069

    Article  PubMed  CAS  Google Scholar 

  13. Charhon SA, Edouard CM, Arlot ME, Meunier PJ (1982) Effects of parathyroid hormone on remodeling of iliac trabecular bone packets in patients with primary hyperparathyroidism. Clin Orthop Rel Res 162:255–263

    Google Scholar 

  14. Gaillard PJ (1961) Parathyroid and bone in tissue culture. In: Greep RO, Talmage RV (eds) The parathyroids. Charles C Thomas, Springfield, Illinois, pp 20–45

    Google Scholar 

  15. Wong GL (1984) Paracrine interactions of bone-secreted products of osteoblasts permit osteoclasts to respond to parathyroid hormone. J Biol Chem 259:4019–4022

    PubMed  CAS  Google Scholar 

  16. Chambers TJ (1985) The pathology of the osteoclast. J Clin Pathol 38:241–252

    PubMed  CAS  Google Scholar 

  17. Gruber HE, Ivey JL, Thompson ER, Chesnut CH II, Baylink DJ (1986) Osteoblasts and osteoclast cell number and cell activity in postmenopausal osteoporosis. Min Electrolyte Metab 12:246–254

    CAS  Google Scholar 

  18. Eriksen EF (1986) Normal and pathological remodeling of human trabecular bone: three-dimensional reconstruction of the remodeling sequence in normals and in metabolic bone diseases. Endocr Rev 7:379–408

    PubMed  CAS  Google Scholar 

  19. Slovik DM, Rosenthal DI, Doppelt SH, Potts JT Jr, Daly MA, Campbell JA, Neer RM (1986) Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1–34) and 1,25-dihydroxyvitamin D. J Bone Min Res 1(4):377–381

    Article  CAS  Google Scholar 

  20. Reeve J, Podbesek RD, Price TR, Arlot M, Bartlett C, Deacon AC, Edouard C, Green JR, Hesp R, Hulme P, Katz D, Tellez M, Zanelli GD, Meunier PJ (1984) Studies for a “short-cycle” ADFR regime using parathyroid peptide hPTH 1–34 in idiopathic osteoporosis and in a dog model. In: Osteoporosis. Proc Copenhagen Int Symp on Osteoporosis

  21. Segre GV, Perkins AS, Witters LA, Potts JT Jr (1981) Metabolism of parathyroid hormone by isolated rat Kupffer cells and hepatocytes. J Clin Invest 67:449–457

    Article  PubMed  CAS  Google Scholar 

  22. Pillai S, Botti R Jr, Zull JE (1983) ATP activation of parathyroid hormone cleavage catalyzed by cathepsin D from bovine kidney. J Biol Chem 258:9724–9728

    PubMed  CAS  Google Scholar 

  23. Martin KJ, Hruska KA, Freitag JJ, Klahr S, Slatopolsky E (1979) The peripheral metabolism of parathyroid hormone. N Engl J Med 301, 20:1092–1098

    Article  PubMed  CAS  Google Scholar 

  24. Harms H, Brabant G, Rittinghaus EF, Atkinson MJ, Hesch RD (in press) Pulsatile secretion of parathyroid hormone and its action on type I and type II receptor: a hypothesis for understanding of osteoporosis. 1st Intl Conf on New Actions of PTH. Kobe, Japan

  25. Delling G, Dreyer T, Hesch RD, Schulz W, Ziegler R, Bressel M (1987) Morphologische Veränderungen der Beckenkammspongiosa beim primärren Hyperparathyreodismus und ihre Bedeutung für die Diagnostik. Klin Wschr 65:643–653

    Article  PubMed  CAS  Google Scholar 

  26. Löwik CWGM, van Leeuwen JPTM, van der Meer JM, van Zeeland JK, Scheven BAA, Herrmann-Erlee MPM (1985) A two receptor model for the action of parathyroid hormone on osteoblasts: a role for intracellular-free calcium and cAMP. Cell Calcium 6:311–326

    Article  PubMed  Google Scholar 

  27. Hesch RD, Herrmann G, Perris AD, Atkinson MJ (1986) Type II PTH receptor-operated calcium channel and its importance for PTH peptide elevations in coronary artery disease. Am J Nephrol 6 (suppl 1):155–161

    Article  PubMed  Google Scholar 

  28. Cambier JC, Newell MK, Justement LB, McGuire JC, Leach KL, Chen ZZ (1987) Ia binding ligands and cAMP stimulate nuclear translocation of PKC in B lymphocytes. Nature 327:629–632

    Article  PubMed  CAS  Google Scholar 

  29. Friedman J, Raisz LG (1965) Thyrocalcitonin: inhibitor of bone resorption in tissue culture. Science 150:629–632

    Google Scholar 

  30. Mazzuoli GF, Passeri M, Gennari C, Minisola S, Antonelli R, Valtorta C, Palummeri E, Cervellin GF, Gonelli S, Francini G (1986) Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study. Calcif Tissue Int 38:3–8

    Article  PubMed  CAS  Google Scholar 

  31. Kleerekoper M, Parfitt AM, Ellis BI (1984) Measurement of vertebral fracture rates in osteoporosis. Proc Copenhagen Intl Symp on Osteoporosis 103–109

  32. Hesch RD, Heck J, Delling G, Keck E, Reeve J, Canzler H, Schober O, Harms H (1988) Results of a stimulatory therapy of low bone metabolism osteoporosis with (1–38)hPTH and diphosphonate EHDP. Klin Wochenschr 66:976–984

    Article  PubMed  CAS  Google Scholar 

  33. Hesch RD, Brabant G, Rittinghaus EF, Atkinson MJ, Harms H (1988) Pulsatile secretion of parathyroid hormone and its action on a type I and type II receptor: a hypothesis for understanding osteoporosis. Calcif Tiss Int 42:341–344

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abteilung für Klinische Endokrinologie, Medizinische Hochschule Hannover, Hannover, Federal Republic of Germany

    Rolf-Dieter Hesch, Ulrike Busch & Ernst-Friedrich Rittinghaus

  2. Abteilung für Radiologie, Medizinische Hochschule Hannover, Hannover, Federal Republic of Germany

    M. Prokop

  3. Institut für Pathologie, Universitätskrankenhaus Eppendorf, Hamburg, Federal Republic of Germany

    Günter Delling

Authors
  1. Rolf-Dieter Hesch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ulrike Busch
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Prokop
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Günter Delling
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ernst-Friedrich Rittinghaus
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hesch, RD., Busch, U., Prokop, M. et al. Increase of vertebral density by combination therapy with pulsatile 1-38hPTH and sequential addition of calcitonin nasal spray in osteoporotic patients. Calcif Tissue Int 44, 176–180 (1989). https://doi.org/10.1007/BF02556561

Download citation

  • Revised:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02556561

Key words

Search

Navigation